Javier Nieto Guevara (Javier Nieto-Guevara, Javier Nieto)

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 13

Top Venues

Human vaccines & immunotherapeutics

Expert review of vaccines

Infectious diseases and therapy

GlaxoSmithKline Panama

Universidad de Panama (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

GlaxoSmithKline Panama Jun 01 2011

Panama

Global Medical Affairs Manager based in Latin America Region :: Medical Affairs

Education History

Universidad de Panama Mar 01 2006 - Mar 01 2008

Panama

MSC :: Facultad de Medicina

Universidad Autónoma de Centro América Jan 08 1990 - Jan 06 1995

Costa Rica

PHD :: School of Medicine

Publications

Ru Han, Jorge A Gomez, Bruna M G de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics 19 (1) (2023)
Ru Han, Jorge A Gomez, Bruna M G de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics 19 (1) (2023)
Ru Han, Jorge A Gomez, Bruna M G de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics (2023)
Ru Han, Jorge A Gomez, Bruna M G de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics 19 (1) (2023)
Ru Han, Jorge A Gomez, Bruna M G de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics 19 (1) (2023)
Adriana Guzmán-Holst, Jorge A Gomez, Otávio Cintra, Désirée A M van Oorschot, Nicolas Jamet, Javier Nieto Guevara
Assessing the Underestimation of Adult Pertussis Disease in Five Latin American Countries. Infectious diseases and therapy (2023)
Ru Han, Jorge A Gomez, Bruna M G de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics 19 (1) (2023)
Patricia Izurieta, Mikhail Scherbakov, Javier Nieto Guevara, Volker Vetter, Bruce A Mungall
Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media. Human vaccines & immunotherapeutics 18 (1) (2022)
Patricia Izurieta, Javier Nieto Guevara
Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease. Human vaccines & immunotherapeutics (2021)
Javier Nieto Guevara, Adriana Guzmán-Holst
Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impact. Human vaccines & immunotherapeutics (2021)
Nicolas Lecrenier, Alen Marijam, Jan Olbrecht, Bruce A Mungall, Javier Nieto Guevara, Bruce A Mungall
Ten years of experience with the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (Synflorix) in children. Expert review of vaccines 19 (3) (2020)
Javier Nieto Guevara, Patricia Izurieta
Reply to 'Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10'. Human vaccines & immunotherapeutics 16 (9) (2020)
Javier Nieto Guevara, Dorota Borys, Rodrigo DeAntonio, Adriana Guzmán-Holst, Bernard Hoet
Interchangeability between pneumococcal conjugate vaccines for pediatric use: a systematic literature review. Expert review of vaccines 19 (11) (2019)

Javier Nieto Guevara.css-eqlu8i{font-size:small;padding-left:4px;} (Javier Nieto-Guevara, Javier Nieto)

Publication Activity (10 Years)

Top Topics

Top Venues

Javier Nieto Guevara (Javier Nieto-Guevara, Javier Nieto)